AmbioPharm peptides are made by a peptide CDMO in North Augusta, SC and China. Learn what the company manufactures, its CordenPharma ties, and safety facts.
AmbioPharm peptides are pharmaceutical-grade peptides produced by AmbioPharm, Inc., a contract development and manufacturing organization based in North Augusta, South Carolina. The company synthesizes peptide active pharmaceutical ingredients and intermediates for drug developers and biotech firms rather than selling finished peptides to consumers. CordenPharma acquired AmbioPharm in 2022, and the business now operates inside a larger global manufacturing network.
That distinction matters. If you landed here while shopping for research peptides, the key point is that AmbioPharm is a business-to-business manufacturer. Vials sold on consumer websites under that name are not sold by the company itself.
What AmbioPharm Actually Manufactures
AmbioPharm focuses on large-scale peptide synthesis for the pharmaceutical industry. Its work spans the full life cycle of a peptide drug, from early process development through commercial supply.
- Peptide APIs — active ingredients used in injectable and other peptide-based medicines.
- Generic peptides — complex, off-patent sequences that require specialized synthesis know-how.
- Peptide intermediates — protected fragments and building blocks used to assemble longer chains.
- Process development and scale-up — moving a synthesis route from grams in a lab to kilograms in a plant.
- Analytical and regulatory support — documentation that supports filings with agencies such as the FDA and EMA.
Most of these projects are custom, meaning each peptide is made to a client's specification under a quality agreement. That is a different model from a catalog supplier that sells the same vial to thousands of buyers.
Ambiopharm Locations and Manufacturing Footprint
Ambiopharm locations span both the United States and Asia, which allows the company to serve Western and Asian drug developers from more than one supply node. The headquarters and primary US site sit in North Augusta, South Carolina.
The company's global footprint also includes peptide operations in China, which support lower-cost production and provide a second manufacturing site. Dual-site capacity matters for peptide drugs because a single-site disruption can stall an entire clinical program.
Peptide Synthesis Technology and Scale-Up
AmbioPharm's core competency is solid-phase peptide synthesis, the standard method for building a peptide one amino acid at a time on a resin. For longer or difficult sequences, fragment-based and hybrid strategies are used instead.
Capabilities the company highlights on the technical side include:
- Synthesis of peptides well beyond 30 amino acids in length.
- Production capacity measured in metric tons per year across sites.
- Handling of linear and modified peptides, including sequences with non-natural amino acids.
- Purification by preparative HPLC and lyophilization to a finished powder.
A peptide that is easy to make at 10 milligrams can become very difficult at 100 kilograms. Scale-up is where many suppliers fail, and it is a large part of what clients pay a specialized CDMO to solve.
CordenPharma AmbioPharm: What the Acquisition Changed
CordenPharma AmbioPharm is the combined organization that formed after CordenPharma, a European CDMO group, bought AmbioPharm in 2022. The deal folded peptide manufacturing into a broader portfolio that also includes lipids, oligonucleotides, and sterile fill-finish.
For drug developers, the practical effects were straightforward:
- Access to more drug substance and drug product services under a single contract.
- Additional capacity for late-phase and commercial peptide programs.
- Integration with CordenPharma's European manufacturing sites.
Coverage of ambiopharm news in the trade press tends to focus on capacity expansion and the broader peptide manufacturing boom, especially demand tied to metabolic and metabolic-adjacent therapies.
How Peptide Suppliers Compare
Not every company selling peptides operates at the same level. The table below outlines the main supplier categories a buyer will encounter.
| Supplier type | Example profile | Typical buyer | Regulatory standing |
|---|---|---|---|
| Peptide CDMO | AmbioPharm and CordenPharma | Pharma and biotech companies | GMP facilities inspected by regulators |
| Research chemical vendor | Catalog peptide shops | Labs and independent researchers | Labeled for research use only; not for human use |
| Asian peptide manufacturers | Wide range of quality and scale | Global buyers, including some pharma | Mixed; audit and documentation vary |
| Generic API producer | Off-patent peptide makers | Generic drug manufacturers | Depends on market filings |
Cost pushes many buyers toward Asia. Anyone searching for the best chinese peptide company will find dozens of contenders, and quality varies widely across them. Checking a chinese peptide company website for third-party test results, audit reports, and clear GMP statements is the minimum due diligence before placing an order.
Safety and Quality: What Buyers Should Verify
Research peptides sold online are not FDA-approved medicines for human use, and they are not manufactured by AmbioPharm for consumer sale. A company name on a label proves nothing about who made the powder in the vial.
- Request a certificate of analysis from an independent laboratory, not just the seller's own document.
- Check whether the facility holds a current GMP registration and has been inspected.
- Treat unknown purity as a real risk; contaminants and wrong sequences have caused harm in published cases.
- Talk with a healthcare professional before using any peptide, since injection-site reactions, immune responses, and hormonal effects are possible.
A certificate of analysis from an independent laboratory is the only reliable evidence that a peptide is what its label claims. Anything less is a marketing statement.
For pharmaceutical buyers, AmbioPharm remains a legitimate development and manufacturing partner with US and Asian capacity. For individual consumers, it is not a source of peptides, and no legitimate CDMO sells to that market.
Frequently Asked Questions
Does AmbioPharm sell peptides to individuals?
No. AmbioPharm is a contract development and manufacturing organization that serves pharmaceutical and biotech companies under custom supply agreements. It does not run a consumer storefront, and consumer websites that use the AmbioPharm name are not affiliated with the company.
Where is AmbioPharm located?
AmbioPharm is headquartered in North Augusta, South Carolina, where its main US peptide manufacturing site operates. The company also has peptide production operations in China, giving it a second manufacturing node. Since 2022 it has been part of the CordenPharma group.
Are AmbioPharm peptides FDA approved?
AmbioPharm's facilities support FDA-regulated drug programs, but approval applies to specific finished drug products, not to a manufacturer's name. Peptides sold online as research chemicals are not FDA-approved medicines for human use and should not be treated as such.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.